Clinical Trial Update: Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for idelalisib (GS-1101) in previously treated indolent non-Hodgkin's lymphoma, including follicular lymphoma, reporting safety and effica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-12-21